Investment Highlights

01
Excellence in Cell Therapy Recognized by 2 Global Pharma
02
Systematic Approach and Highly Differentiated Pipeline
03
End-to-end R&D and CMC Capabilities
04
Lower valuation than peers given development progress, growth catalysts and addressable market size.
05
Top Notch Leadership Backed by MNCs and Renowned Investors
06
Assets with first-to-market & best-in-class potentials

Press Release re going private

Our strategy is to commercialize both home grown and partnered cellular medicine technologies in a safe and efficient manner